Abstract: A process can be used for oligomerization of isobutene by conversion of an isobutene-containing hydrocarbon stream over an acid catalyst in at least one reaction stage, where a particular ratio of recycle to feed is employed.

Abstract: Linear alpha olefins (LAOS) may be formed by oligomerization of ethylene in the presence of a Ziegler-type catalyst. The presence of trace water during oligomerization can result in unwanted formation of insoluble higher oligomers or polymer. Methods for limiting the presence of water during ethylene oligomerization reactions may include separating residual ethylene and 1-butene from an LAO product stream to form a higher LAO-enriched stream comprising C6+ LAOs, separating 1-hexene as an overhead stream from the higher-LAO enriched stream using a first distillation column, obtaining separated solvent as a side stream from the first distillation column or as a side stream from a first of one or more downstream distillation columns, and returning the separated solvent to a reactor in a recycled solvent stream. The recycled solvent stream passes through one or more driers before returning to the reactor.

Abstract: In a method, device, catalyst and a method for producing a catalyst for the catalytic conversion of a substance mixture containing glycerol to propanol in a fixed-bed reactor, substrates of the catalyst have inorganic materials and/or metal oxides. The substrates have a pore diameter at the surface of between 10 and 25 angstroms, preferably between 12 and 20 angstroms, particularly preferably 15 angstroms.

Abstract: The invention relates to a process and a plant for producing pure methanol, wherein the crude methanol stream discharged from a methanol synthesis unit is decompressed in a decompression vessel, is subsequently at least partially freed of low-boiling by-products in a prerun column and is then supplied to a single- or multi-stage methanol purification apparatus from which a pure methanol product stream is finally discharged. According to the invention the tops product stream from the prerun column is subjected to a scrubbing step with a methanol-selective scrubbing medium, thus at least partially recovering methanol present and sending a methanol-depleted tops product stream to the offgas disposal apparatus.

Abstract: The present application describes process for preparing an ortho-allylated hydroxy aryl compounds such as compounds of Formula (I) by reacting an allylic alcohol with a hydroxy aryl compound in the presence of aluminum compound selected from alumina and aluminum alkoxides and in a non-protic solvent wherein at least one carbon atom ortho to the hydroxy group in the hydroxy aryl compound is unsubstituted. The present application also includes compounds of Formula (I).

Abstract: The present disclosure provides a method for forming oxygenates from olefins which includes hydroformylation of aldehydes as a formyl source alternative to syngas. In at least one embodiment, a hydroformylation process is performed at low-temperature and at or near ambient pressure for the conversion of olefins into aldehydes, thus reducing the formation of by-products such as via double bond or skeletal isomerization of the feedstock; or via further conversion of the formed aldehydes and alcohols. In at least one embodiment, the use of gaseous olefinic products (e.g., ethylene) instead of strained olefins (e.g., norbornene) improves the control equilibria in transfer hydroformylation reactions.

Abstract: The present application pertains to methods for making metal oxides and/or citric acid and/or capturing carbon dioxide. In one embodiment, the application pertains to a process for producing calcium oxide, magnesium oxide, or both from a material comprising calcium and magnesium. The process may include reacting a material comprising calcium carbonate and magnesium carbonate. Separating, concentrating, and calcining may lead to the production of oxides such as calcium oxide or magnesium oxide. In other embodiments the application pertains to methods for producing an alkaline-earth oxide and a carboxylic acid from an alkaline earth cation-carboxylic acid anion salt. Such processes may include, for example, reacting an alkaline-earth cation-carboxylic acid anion salt with aqueous sulfur dioxide to produce aqueous alkaline-earth sulfite or bisulfite and an aqueous carboxylic acid solution. Other useful steps may include desorbing, separating, and/or calcining.

Abstract: The present invention provides a process for producing a compound represented by formula (I), comprising the steps of (a) reacting a compound represented by formula (II) with dimethyl sulfate in the presence of an alkali carbonate in a aqueous ketone solvent to obtain the compound represented by formula (I) as a crystalline material, and (b) washing the crystalline material with heated water at 30 to 100° C. and then further washing with an organic solvent at 30 to 80° C.

Abstract: Tetraphenylene triarylamine compounds are disclosed, which are novel triarylamine compounds containing tetraphenylene building block. The compounds can be used as charge transporting materials, hole transporting materials, hole injection materials, electron blocking materials, etc., in an electroluminescent device. These novel compounds have good sublimation characters, and can offer more controllable charge transporting performance and good OLED device performance. Also disclosed are an organic electroluminescent device and a formulation.

Abstract: The present disclosure relates to an aromatic amine derivative represented by general formula (I). The aromatic amine derivative has fluorescence emission at a short light emission wavelength, and the light-emission spectrum of the aromatic amine derivative has a narrow half-peak width, and accordingly, the material has deep-blue fluorescence emission and has a very-high light emission efficiency. An organic electroluminescent component prepared by using the aromatic amine derivative has deep-blue color coordinates, a high light emission efficiency and a long life-span.

Abstract: A process for the preparation of amino alcohols includes condensing a compound of Formula (II), a stereoisomer, a tautomer, or a salt thereof with a compound of Formula (IIIa) or Formula (IIIb), a stereoisomer, a tautomer, or a salt thereof to form a condensation product; hydroxylating or acyloxylating the condensation product in the presence of an oxidant to obtain a hydroxylation or acyloxylation product; and subjecting the hydroxylation or acyloxylation product to one or more subsequent reactions comprising a hydrolysis reaction, alcohol deprotection, an amino lysis reaction, or a combination of two or more thereof to obtain an amino alcohol of Formula (I).

Abstract: Disclosed herein is a method of forming a compound of formula I: wherein the substituents are defined in the specification. In particular, the compounds of formula I can be converted to amino acids bearing quaternary stereocenters with exceptional optical purities.

Abstract: The present invention describes compounds and uses thereof in applications relating to absorption of electromagnetic energy. Preferred compounds are double bond-containing compounds capable of absorbing electromagnetic radiation energy and having improved properties.

Abstract: The invention relates to a process for preparing N-methyl(meth)acrylamide and to the uses thereof.

Abstract: Disclosed is a method for preparing salicylamine acetate. The method comprises the steps of: (1) carrying out amino protection on salicylaldehyde having a structure represented by formula 1 to obtain a compound having a structure represented by formula 2; and (2) carrying out acid hydrolysis to the compound having a structure represented by formula 2 and then reacting the acid-hydrolyzed compound with acetic acid to obtain salicylamine acetate.

Abstract: The invention concerns synthesized amido-amine-based cationic gemini surfactants with flexible and rigid spacers and different hydrophobic. These gemini surfactants were prepared by modified procedure through amidation of long chain carboxylic acids using 3-(dimethylamino)-1-propylamine followed by treatment with halohydrocarbons and showed excellent thermal stability and surface properties useful for various oilfield applications such as enhanced oil recovery.

Abstract: A process for preparing an aromatic isocyanate by direct carbonylation of a nitro aromatic compound by reacting the nitro aromatic compound with carbon monoxide in the presence of a catalyst, characterized in that the catalyst contains a multi metallic material comprising one or more binary intermetallic phases of the general formula AxBy wherein: A is one or more element selected from Ni, Ru, Rh, Pd, Ir, Pt and Ag, B is one or more element selected from Sn, Sb, Pb, Zn, Ga, In, Ge and As, x is in the range 0.1-10, y in is in the range 0.1-10.

Abstract: The present invention relates to a new crystal modification of N-(aminoiminomethyl)-2-aminoacetic acid as well as a method for producing this crystal modification.

Abstract: The presently claimed invention relates to a color developer, a process for its manufacture and its use as a component in heat sensitive recording material. The heat sensitive recording material is useful for thermographic printing.

Abstract: A compound with anti-drug resistant bacteria activity having the formula (I): (I) is disclosed. The methods of preparing the compound of formula (I) are also disclosed.

Abstract: The present invention relates to a process for synthesizing hydroperoxy alcohols by perhydrolysis of epoxides, using an aqueous solution of hydrogen peroxide, in the presence of a catalyst consisting of phosphotungstic acid.

Abstract: Disclosed are compounds having potency in the modulation of NMDA receptor activity. Such compounds can be used in the treatment of conditions such as depression and related disorders. Orally delivered formulations and other pharmaceutically acceptable delivery forms of the compounds, including intravenous formulations, are also disclosed.

Abstract: A genus of dihydropyridine chemical modulators of synaptojanin is disclosed. These modulators are selective inhibitors of synaptojanin 1 and may be used to treat cognitive impairment or traumatic brain injury, including promoting regeneration in cases of traumatic brain injury, or for treating neurodegenerative disorders.

Abstract: Described herein are compounds of Formula (I), pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof. Compounds described herein are useful for inhibiting arginine methyltransferase activity. Methods of using the compounds for treating arginine methyltransferase-mediated disorders are also described.

Abstract: The present invention relates to the compounds of formula (I), and the N-oxides, stereoisomers, tautomers and agriculturally or veterinarily acceptable salts thereof wherein the variables are defined according to the description, formula (I). The compounds of formula (I), as well as the N-oxides, stereoisomers, tautomers and agriculturally or veterinarily acceptable salts thereof, are useful for combating or controlling invertebrate pests, in particular arthropod pests and nematodes. The invention also relates to a method for controlling invertebrate pests by using these compounds and to plant propagation material and to an agricultural and a veterinary composition comprising said compounds.

Abstract: The present invention relates to benzimidazole derivatives of formula (I) as inhibitors of retinoid-related orphan receptor gamma (ROR?) protein, pharmaceutical compositions containing the compounds, preparation methods thereof, and the use of the compounds as therapeutic agents for the treatment of ROR?-mediated diseases or disorders.

Abstract: A P2Y12 receptor antagonist containing a guanidyl, and a preparation method and the use thereof. In particular, the present disclosure provides a pyridazinone-guanidine compound that is a compound of structural formula (I), or a stereoisomer of the above-mentioned compound, a pro-drug thereof, a pharmaceutically acceptable salt thereof or a pharmaceutically acceptable solvate thereof. Such a compound has multiple pharmacological activities, especially has an inhibitory effect on platelet aggregation, and can be used for preparing an anti-platelet aggregation pharmaceutical composition.

Abstract: The present invention discloses unsaturated hydrocarbon pyrimidine thioether compounds of formula (I) and preparation method and application thereof, the compounds of formula (I) exhibit high insecticidal and acaricidal activity against adults, larvae and eggs of harmful mites and insects in the agriculture, civil use and animal technology fields, meanwhile, the compounds also exhibit good bactericidal activity, and can be widely applied as an insecticide, an acaricide and/or a bactericide in agriculture or other fields

Abstract: The invention provides compounds of Formula (I), or pharmaceutically acceptable salts thereof: The compounds, compositions, methods and kits of the invention are useful for the treatment of pain, cough, itch, and neurogenic inflammation.

Abstract: Aminocyclobutane compounds of Formula (I), and pharmaceutically acceptable salts, isotopes, N-oxides, solvates, and stereoisomers thereof, pharmaceutical compositions containing them, and methods of using them including methods for treating disease states, disorders, and conditions associated with MGL modulation, such as those associated with pain, psychiatric disorders, neurological disorders (including, but not limited to major depressive disorder, treatment resistant depression, anxious depression, autism spectrum disorders, Asperger syndrome, bipolar disorder), cancers and eye conditions: wherein X, R1, R2a, R2b, R3 and R4 are defined herein.

Abstract: The present invention relates to pharmaceutical compositions of 1,2,4-oxadiazole compounds or a pharmaceutically acceptable salt thereof of formula (I) In the formula Q is O, R1 is the side chain of Ser, R2 is —CO-Thr, R3 is the side chain of Asn or Glu, and R4, R5 and R6 are each H.

Abstract: An ammonium salt having a saccharin anion, which is represented by formula (1), exhibits excellent thermal stability even though no halogen atom is contained therein. (In the formula, each of R1-R4 independently represents an alkyl group having 1-4 carbon atoms or an alkoxyalkyl group that is represented by —(CH2)n—OR (wherein R represents an alkyl group having 1-4 carbon atoms, and n represents an integer of 1 or 2). Incidentally, any two of the R1-R4 may combine with each other to form a ring together with a nitrogen atom.

Abstract: Process for the industrial synthesis of the compound of formula (I):

Abstract: A method for synthesizing functionalized bio-based crosslinkers including forming a first mixture by mixing a bio-based carboxylic acid with an alkaline solution and forming a second mixture containing a functionalized bio-based crosslinker by reacting the bio-based carboxylic acid with a modifier. The modifier includes at least one of an epoxide group and an acrylate group. Reacting the bio-based carboxylic acid with the modifier includes forming a reaction mixture by mixing the first mixture with the modifier and exposing the reaction mixture to at least one of heating, ultrasound radiation, and microwave radiation.

Abstract: The present invention relates to processes and intermediates for preparing 3-(cyanomethyl)-3-(4-{[(1R,2S)-2-phenylcyclopropyl]amino}piperidin-1-yl)azetidine-1-sulfonamide, and salts and solid forms thereof, which selectively modulate demethylase. Particular embodiments contemplate compounds and disease indications amenable to treatment by modulation of lysine specific demethylase-1 (LSD1).

Abstract: This disclosure is directed, at least in part, to GPR119 agonists useful for the treatment of conditions or disorders involving the gut-brain axis. In some embodiments, the GPR119 agonists are gut-restricted compounds. In some embodiments, the condition or disorder is a metabolic disorder, such as diabetes, obesity, nonalcoholic steatohepatitis (NASH), or a nutritional disorder such as short bowel syndrome.

Abstract: The present invention provides compounds of formula (I) and pharmaceutically acceptable salts thereof in which q, R11, R12, R13 and R14 are as defined in the specification, for use in therapy.

Abstract: An object of the present invention is to provide a compound having an anti-inflammatory activity or a pharmacologically acceptable salt thereof. The solution of the present invention is a compound of general formula (1) or a pharmacologically acceptable salt thereof. wherein the symbols in the formula are defined below: A: e.g., Benzene, E: e.g., —CH2—, G: e.g., a 5-membered aromatic heterocyclic ring, X: e.g., cyclohexane, J: e.g., a 5-membered aromatic heterocyclic ring, Y: e.g., a phenyl group, R1, R2, R3: e.g., a halogen atom, R4: e.g., a C1-C6 alkyl group, R5: e.g., a hydrogen atom, R6a, R6b, R6c, R6d: e.g., a hydrogen atom, R7: e.g., a hydrogen atom, R8: e.g., a hydrogen atom, n1, n2, n3: e.g., 1.

Abstract: The invention relates to acid addition salts of ridinilazole and processes for the preparation of ridinilazole using these acid addition salts. In addition, the present invention relates to processes for the preparation of ridinilazole in pure form using acid addition salts of ridinilazole as process intermediates.

Abstract: A method of administering to a patient in need thereof or contacting with a biological sample, a compound related to Formula I-e or pharmaceutically acceptable compositions thereof, is useful to inhibit activity of TLR7/8 or a mutant thereof and/or to treat a TLR7/8-mediated disorder.

Abstract: Provided herein are 6-carboxylic acids of benzimidazoles and 4-aza-, 5-aza-, 7-aza- and 4,7-diaza-benzimidazoles as GLP-1R agonists, processes to make said compounds, and methods comprising administering said compounds to a mammal in need thereof.

Abstract: Methods described herein enable the production of numerous molecular species through decarboxylative cross-coupling via use of photoredox and transition metal catalysts. For example, methods described herein enable the production of numerous molecular species through decarboxylative cross-coupling via use of photoredox and transition metal catalysts. A method described herein, in some embodiments, comprises providing a reaction mixture including a photoredox catalyst, a transition metal catalyst, a coupling partner and a substrate having a carboxyl group. The reaction mixture is irradiated with a radiation source resulting in cross-coupling of the substrate and coupling partner via a mechanism including decarboxylation, wherein the coupling partner is selected from the group consisting of a substituted aromatic compound and a substituted aliphatic compound.

Abstract: The present disclosure provides azetidine compounds of Formula I and their pharmaceutically acceptable salts, their compositions, and methods for their use in determining azetidine compound binding to proteins. The azetidine compounds are useful as probes, for monitoring diacylglycerol kinase activity, and for identifying druggable targets.

Abstract: Disclosed is a compound of Formula I or a pharmaceutically acceptable salt thereof, and pharmaceutical composition comprising the same, and use thereof in the treatment of diseases benefiting from the inhibition of autophagic flux and/or chromatin ubiquitination, especially in the treatment of breast cancer.

Abstract: A substituted amino heterocyclic carboxamide compound as represent by formula (?), or a pharmaceutically acceptable salt, a prodrug, a hydrate or a solvent compound, a crystal form, a stereoisomer or an isotopic variant of the compound, and a pharmaceutical composition thereof, and the use thereof as an FLT3/AXL kinase inhibitor for treating acute myelocytic leukemia.

Abstract: The invention provides 20-nor-salvinorin A, an analog of the kappa-opioid agonist salvinorin A. The 20-nor-salvinorin A is an active kappa-opioid modulator and can be used for treatment of medical conditions wherein modulation of the kappa-opioid receptor is medically indicated, such as pain, pruritis, depression, or inflammation, or conditions implicating perception and consciousness. 20-nor-salvinorin A can be less additive when used in treatment compared to a mu-opioid receptor agonist, and 20-nor-salvinorin A is more stable in vivo than is parent compound salvinorin A. The invention further provides synthetic intermediates and procedures for preparation of 20-nor-salvinorin A.

Abstract: Provided are a compound of Formula 1; an organic electric element comprising a first electrode, a second electrode, and an organic material layer formed between the first electrode and the second electrode, comprising a compound of Formula 1 in the organic material layer; and an electronic device comprising the element, which has lowered driving voltage and increased luminous efficiency and life time.

Abstract: Disclosed in the present application are a salt form and a crystal form of an S1P1 receptor mediated disease or symptom drug 1-{2-fluoro-4-[5-(4-isobutylphenyl)-1,2,4-oxadiazole-3-yl]benzyl}-3-azetidinecarboxylic acid (formula A). Also disclosed in the present invention are a preparation method for the salt form or the crystal form, a pharmaceutical composition of the salt form or the crystal form, and use of the salt form or the crystal form in the preparation of a drug for treating and/or preventing an S1P1 receptor mediated disease or symptom.

Abstract: Described herein are heterocycle substituted pyridine derivative antifungal agents and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for the treatment of fungal diseases and infections.

Abstract: The present invention provides compounds, compositions thereof, and methods of using the same for the inhibition of CRBN, and the treatment of CRBN-mediated disorders.